Inventors:
Richard Weber - San Francisco CA, US
Xiao Feng - Union City CA, US
Orit Foord - Foster City CA, US
Larry Green - San Francisco CA, US
Jean M. Gudas - Santa Monica CA, US
Bruce Keyt - Hillsborough CA, US
Ying Liu - Palo Alto CA, US
Palaniswami Rathanaswami - Vancouver, CA
Robert Raya - Fremont CA, US
Xiao Dong Yang - Palo Alto CA, US
Jose Corvalan - Foster City CA, US
Ian Foltz - Burnaby, CA
Xiao-Chi Jia - Los Angeles CA, US
Jaspal S. Kang - Surrey, CA
Chadwick T. King - Vancouver, CA
Scott L. Klakamp - Fremont CA, US
Qiaojuan Jane Su - San Jose CA, US
Assignee:
Amgen Fremont Inc. - Fremont CA
International Classification:
A61K 39/00
A61K 39/395
C07K 16/00
C07K 16/18
C07K 16/28
C12P 21/08
US Classification:
4241301, 4241411, 4241431, 4241781, 4241791, 435810, 5303871, 5303881, 53038815, 53038822, 5303911
Abstract:
The present invention relates to novel antibodies, particularly antibodies directed against deletion mutants of epidermal growth factor receptor and particularly to the type III deletion mutant, EGFRvIII. The invention also relates to human monoclonal antibodies directed against deletion mutants of epidermal growth factor receptor and particularly to EGFRvIII. Diagnostic and therapeutic formulations of such antibodies, and immunoconjugates thereof, are also provided.